Orlin Petrov

This inventor holds 24 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 3 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Schering Aktiengesellschaft, Bayer Schering Pharma Ag, Bayer Intellectual Property Gmbh. Active years: 1997-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Orlin Petrov. Retrieved from https://idiyas.com/inventor/orlin-petrov

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 (Patent Applications = 2)

% Patents Active = 20.8

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 3 (Patent Applications = 11)

Average Co-Inventor Count = 4.5

ph-index = 5

Forward Citations = 64(Granted Patents)

Company Filing History:

12 out of 1,409

Schering Aktiengesellschaft

patents

7 out of 192

Bayer Schering Pharma Ag

patents

1 out of 721

Bayer Intellectual Property Gmbh

patents

4. 1 out of 387

Bayer Pharma Aktiengesellschaft

patents

5. 1 out of 51

Cis Bio International

7. 1 out of 834,570

Other

patents

Years Active: 1997-2017

Loading Chart...

Areas of Expertise:

Epothilones

Progesterone Antagonists

Anti-Inflammatory Agents

Chiral Derivatives

Heteroaromatic Compounds

Dihydroimidazoquinolines

Anthranilic Acid Amides

Catalytic Epoxidation

Lithium Complexes

C-Substituted Diethylenetriamines

Valeroamides

Pharmaceutical Preparations

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9675616 - Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-C]quinolines (2017-06-13),

2. 8314248 - Process for preparing epothilone derivatives by selective catalytic epoxidation (2012-11-20),

3. 8053426 - Progesterone receptor antagonists (2011-11-08),

4. 7935827 - Optically active, heteroaromatic β-hydroxy esters and processes for their preparation from β-keto esters and processes for the preparation of these β-keto esters (2011-05-03),

5. 7659364 - N-methyl-homocysteines and their use as well as process for their production (2010-02-09),

6. 7626035 - Optically active, heteroaromatic β-hydroxy esters and processes for their preparation from β-keto esters and processes for the preparation of these β-keto esters (2009-12-01),

7. 7595418 - Protected 5,7-dihydroxy-4,4-dimethyl-3-oxoheptanoic acid esters and 5,7-dihydroxy-2-alkyl-4,4-dimethyl-3-oxoheptanoci acid esters for the synthesizing of epothilone and epothilone derivatives and process for the production of these esters (2009-09-29),

8. 7538100 - 17α-alkyl-17β-oxy-estratrienes and intermediate products for their production, use of the 17α-alkyl-17β-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations (2009-05-26),

9. 7417056 - 5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents (2008-08-26),

10. 7368568 - Protected 3,5-dihydroxy-2,2-dimethyl-valeroamides for the synthesis of epothilones and derivatives and process for production and the use (2008-05-06),

11. 7358382 - Protected 3,5-dihydroxy-2,2-dimethyl-valeronitriles for the synthesis of epothilones and epothilone derivatives and process for the production (2008-04-15),

12. 7326798 - Chiral heptyne derivatives for the preparation of epothilones and processes for their preparation (2008-02-05),

13. 7189879 - Process for the production of 1-hydroxymethyl-1,3,5-triazapentane, trihydrochloride (2007-03-13),

14. 7081468 - Ortho-substituted anthranilic acid amides and their use as medicaments (2006-07-25),

15. 7034165 - Protected 3,-5-dihydroxy-2,2-dimethyl-valeronitriles for the synthesis of epothilones and epothilone derivatives and process for the production (2006-04-25),

Title: The Innovative Contributions of Orlin Petrov in Pharmaceutical Chemistry

Introduction

Orlin Petrov is a prominent inventor based in Berlin, Germany, known for his significant contributions to the field of pharmaceutical chemistry. With a remarkable portfolio consisting of 24 patents, Petrov has been at the forefront of developing novel compounds and processes that have the potential to address various medical challenges.

Latest Patents

Among Petrov's latest innovations is the patent titled "Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-C]quinolines." This invention focuses on substituted phenoxypyridine compounds that present various applications in pharmaceutical compositions for treating hyper-proliferative and angiogenesis disorders. The patent outlines methods of preparing these compounds, along with their intermediates and combinations with other active ingredients.

Another notable patent is for a "Process for preparing epothilone derivatives by selective catalytic epoxidation." This innovative process utilizes substituted pyridines and methyltrioxorhenium as a catalyst, providing a novel approach towards synthesizing epothilone derivatives, which have implications in cancer treatment.

Career Highlights

Orlin Petrov's career includes significant tenures at leading pharmaceutical companies, such as Schering Aktiengesellschaft and Bayer Schering Pharma AG. His experiences in these companies have equipped him with extensive knowledge and expertise in developing innovative pharmaceutical solutions, enabling him to file and secure numerous patents throughout his career.

Collaborations

Throughout his career, Petrov has collaborated with notable coworkers, including Johannes Platzek and Jurgen Westermann. These partnerships have furthered his research capabilities, fostering an environment where innovative ideas can flourish and lead to impactful inventions in the pharmaceutical industry.

Conclusion

Orlin Petrov continues to be a key figure in the world of pharmaceutical innovations. His extensive work and patent contributions not only highlight his expertise but also demonstrate the potential of his inventions to address significant health conditions. Through both collaboration and innovation, Petrov is making strides in improving therapeutic options, showcasing the importance of research and development in the medical field.

Profile summary based on public USPTO records.